Full text is available at the source.
Abstract
Specific microbial communities are associated with the efficacy and toxicity of immune checkpoint inhibitors in cancer immunotherapy.
- The gut microbiome plays a crucial role in influencing clinical outcomes in cancer treatment.
- Mechanisms include the microbiome's impact on immune system functions such as antigen presentation and activation of immune cells.
- Certain microbial components may enhance or inhibit the effectiveness of cancer therapies through various biological pathways.
- Microbiome-targeted strategies like antibiotics, probiotics, and dietary changes could serve as potential complementary therapies for improving treatment outcomes.
- Challenges remain in applying preclinical findings to standardized clinical practices.
Simplified